Please use this identifier to cite or link to this item:
Title: Quantification of trans-2,6-difluoro-4'-N,N-dimethylaminostilbene in rat plasma: Application to a pharmacokinetic study
Authors: Lin, H.-S. 
Sviripa, V.M.
Watt, D.S.
Liu, C.
Xiang, T.-X.
Anderson, B.D.
Ong, P.S. 
Ho, P.C. 
Keywords: Absolute oral bioavailability
Issue Date: 18-Jan-2013
Citation: Lin, H.-S., Sviripa, V.M., Watt, D.S., Liu, C., Xiang, T.-X., Anderson, B.D., Ong, P.S., Ho, P.C. (2013-01-18). Quantification of trans-2,6-difluoro-4'-N,N-dimethylaminostilbene in rat plasma: Application to a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis 72 : 115-120. ScholarBank@NUS Repository.
Abstract: trans-2,6-Difluoro-4'-N,N-dimethylaminostilbene (DFS), a synthetic stilbene, displayed potent pre-clinical anti-cancer activities exceeding that observed for naturally occurring resveratrol. In this study, a simple and sensitive HPLC method was developed and validated to quantify DFS in rat plasma. The lower limit of quantification (LLOQ) was 5ng/ml. The intra- and inter-day variation in terms of relative standard deviation (RSD) was all less than 10%. The bias rate ranged from -11.5% to 6.2% while the absolute recovery ranged from 94.1±2.3 to 97.3±4.4%. The pharmacokinetic profiles of DFS were examined in Sprague-Dawley rats after intravenous administration (2 mg/kg). DFS displayed moderate clearance (Cl=61.5±17.7ml/min/kg) and a relatively prolonged terminal elimination half-life (t1/2 λz) of 351±180min. Aqueous solubility played a crucial role in the oral absorption of DFS. When DFS was given as a suspension (6mg/kg), the absolute oral bioavailability (F) was almost negligible. However, when DFS was given in a solution prepared with hydroxypropyl-β-cyclodextrin (6mg/kg), the F was 12.4±10.7%. Dose-escalation to 15mg/kg resulted in much higher systemic exposure (F=40.2±10.0%). As DFS is orally available after formulation with hydroxypropyl-β-cyclodextrin and pharmacologically active systemic concentrations could be achieved after a single oral dose, the use of DFS as a cancer chemopreventive/chemotherapeutic agent is possible. © 2012 Elsevier B.V.
Source Title: Journal of Pharmaceutical and Biomedical Analysis
ISSN: 07317085
DOI: 10.1016/j.jpba.2012.09.027
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on May 26, 2023


checked on May 26, 2023

Page view(s)

checked on May 25, 2023

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.